Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

Autor: D'Haens, Geert, Vermeire, Severine, Lambrecht, Guy, Baert, Filip, Bossuyt, Peter, Pariente, Benjamin, Buisson, Anthony, Bouhnik, Yoram, Filippi, Jérôme, vander Woude, Janneke, Van Hootegem, Philippe, Moreau, Jacques, Louis, Edouard, Franchimont, Denis, De Vos, Martine, Mana, Fazia, Peyrin-Biroulet, Laurent, Brixi, Hedia, Allez, Matthieu, Caenepeel, Philip, Aubourg, Alexandre, Oldenburg, Bas, Pierik, Marieke, Gils, Ann, Chevret, Sylvie, Laharie, David, Détré, Patricia, Bertin, Marie Jo, Williams, Sabrina, GETAID

Background & Aims: A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10691::3f0d0d01725af39b60bfadeea905c5fe
https://dspace.library.uu.nl/handle/1874/364570

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.

Autor: D'Haens G; Academic Medical Centre, Amsterdam, the Netherlands. Electronic address: g.dhaens@amc.uva.nl., Vermeire S; University Hospitals Leuven, Leuven, Belgium., Lambrecht G; Damiaan Hospital, Oostende, Belgium., Baert F; AZ Delta, Roeselare, Belgium., Bossuyt P; Imelda Hospital, Bonheiden, Belgium., Pariente B; Hospital Claude Huriez, Lille, France., Buisson A; Hospital Estaing, Clermont-Ferrand, France., Bouhnik Y; Hospital Beaujon, Clichy, France., Filippi J; Hospital Archet, Nice, France., Vander Woude J; Erasmus MC, Rotterdam, the Netherlands., Van Hootegem P; Sint-Lucas Hospital, Brugge, Belgium., Moreau J; CHU Toulouse, Toulouse, France., Louis E; Hospital Sart-Tilman, Liège, France., Franchimont D; Hopital Universitaire Erasme, Brussels, Belgium., De Vos M; UZ Gent, Ghent, Belgium., Mana F; AZ VUB, Brussels, Belgium., Peyrin-Biroulet L; Hospital Brabois, Nancy, France., Brixi H; CHU Reims, Reims, France., Allez M; Hopital St Louis, Paris, France., Caenepeel P; ZOL Genk, Genk, Belgium., Aubourg A; CHRU Tours, Tours, France., Oldenburg B; UMC Utrecht, Utrecht, the Netherlands., Pierik M; MUMC Maastricht, the Netherlands., Gils A; KU Leuven, Leuven, Belgium., Chevret S; DBIM, Hospital Saint-Louis, Paris, France., Laharie D; Hospital Haut-Leveque, Pessac, France.

Publikováno v: Gastroenterology [Gastroenterology] 2018 Apr; Vol. 154 (5), pp. 1343-1351.e1. Date of Electronic Publication: 2018 Jan 06.